Cancer drug plus the Pill relieves endometriosis

	Tweet

US Investigators report, that A drug used to treat and prevent Breast cancer, Arimidex, can significantly reduce the pain of endometriosis when taken daily along with an oral contraceptive.

Endometriosis is a condition in which the endometrium, tissue that normally lines the uterus, grows in other areas of the body, causing pain, irregular bleeding, and frequently infertility.

The tissue growth typically occurs in the pelvic area, outside of the uterus, on the ovaries, bowel, rectum, bladder, and the delicate lining of the pelvis, but it can occur in other areas of the body as well.

Current treatments for endometriosis are ineffective for many women or have dangerous side effects, Dr. Serdar E. Bulun, from Northwestern University in Chicago, and his associates note in the medical journal Fertility and Sterility.

Arimidex inhibits an enzyme, aromatase, involved in estrogen synthesis, and it was recently found that high levels of aromatase are expressed in endometrial tissue of women with endometriosis.

Bulun’s group theorized that Arimidex (generic name, anastrozole) would block aromatase from producing estrogen in the endometrial tissue. An oral contraceptive would prevent the Osteoporosis associated with aromatase inhibitor drugs.

In their study the investigators treated 18 women, who had failed at least two other treatments for endometriosis, with anastrozole and the Alesse oral contraceptive daily for 6 months.

Fourteen of the 15 women who completed the study experienced significant reductions in pelvic pain. By the end of the first month, the average pain score on a 10-point visual scale fell from 8.70 to 6.20, and by the end of 6 months it was 3.20.

Side effects were mild and improved as the trial progressed. The researchers think that with a longer trial, endometriosis pain and side effects might resolve completely.

The one woman who became pregnant experienced no complications and delivered a normal healthy infant.

“This is an exciting new development in the treatment of a condition with only a limited number of treatments available,” the team concludes.

This study was partially funded by AstraZeneca, the maker of Arimidex.

SOURCE: Fertility and Sterility, August 2005.

RELATED STORIES:
Metronidazole/nystatin effective for vaginosis   Women Encouraged To Ask About Heart Health   Botox-type drug helpful for vaginal spasm disorder   Vaginal contraceptive ring reduces bleeding days   Single moms more likely to have girls   New Clinical Practice Guidelines on the Treatment of Hirsutism   Hospitals best for vaginal birth after C-section   Certain dietary supplements associated with increased risk of death in older women   Inadequate diet can lead to anemia in postmenopausal women   Gender inequality persists in multitasking: study   Before You Have A Hysterectomy   Fewer women than men use rehab after heart attack

Comments

[ + Post Your Own ]

Now you're in the public comment zone. What follows is not Armenian Medical Network's stuff; it comes from other people and we don't vouch for it. A reminder: By using this Web site you agree to accept our Terms of Service. Click here to read the Rules of Engagement.

There are no comments for this entry yet. [ + Comment here + ]